The University of Southampton
University of Southampton Institutional Repository

PCN113 - Cost effectiveness of Cetuximab and Panitumumab for first-line RAS WT metastatic colorecal cancer

PCN113 - Cost effectiveness of Cetuximab and Panitumumab for first-line RAS WT metastatic colorecal cancer
PCN113 - Cost effectiveness of Cetuximab and Panitumumab for first-line RAS WT metastatic colorecal cancer
Objectives
Liver resection is a treatment offering long-term survival in patients with metastatic colorectal cancer (mCRC). However, the majority of such patients are not suitable for curative hepatectomy due to widespread nature of their disease. Chemotherapy can significantly downsize primarily unresectable metastases and increase the possibility of resection in mCRC patients. It has been shown that chemotherapy combined with biological agents, cetuximab (CET) and panitumumab (PAN), is clinically beneficial for treating RAS WT tumors (tumors without mutations in KRAS/NRAS exons 2/3/4). This study is aimed: (1) to estimate the cost-effectiveness of combination chemotherapies with CET and PAN for people with previously untreated RAS WT mCRC, not eligible for liver surgery; and (2) to assess CET and PAN against the National Institute for Health and Care Excellence (NICE) end-of-life (EoL) criteria, to inform a Health Technology Assessment for NICE.

Methods
We proposed an economic model estimating costs and benefits of mCRC treatments over patient lifetime horizon. In our base case, we estimated incremental cost-effectiveness ratio (ICER) for CET+FOLFOX versus FOLFOX, PAN+FOLFOX versus FOLFOX, and CET+FOLFIRI versus FOLFIRI. Probabilistic and univariate deterministic sensitivity analyses were performed to estimate uncertainty in model predictions. The cost-utility analysis was based on three randomised controlled trials and undertaken from the NHS and personal social service perspective. Estimated costs and quality-adjusted life years were discounted at 3.5% per annum.

Results
CET and PAN are not cost-effective at willingness-to-pay thresholds of £30,000. Moreover, ICERs remain above £30,000 even under zero prices for CET and PAN. Based on the available evidence, neither CET nor PAN fulfils the NICE EoL criteria to be considered as life-extending EoL treatments.

Conclusions
Although CET and PAN appear to be clinically beneficial for RAS WT patients, they are likely to represent poor value for money when judged by cost-effectiveness criteria used in the UK.
1098-3015
A154-A154
Tikhonova, I.
577ccbcc-6643-4190-bb6d-19e13b44bcd1
Hoyle, M.
ebc06a93-bd41-4c23-8c96-1d9e74512c38
Snowsill, T.
33dbf192-8a97-43ed-9317-538d41cf498f
Crathorne, L.
f12cef06-0f01-4a1f-8dde-cbfbfbdaa557
Varley-Campbell, J.
0952839e-b1f4-4e45-b538-6dfc7936f259
Peters, J.
3c661fd3-23a3-4bd9-9379-b98b0a84d28f
Briscoe, S.
741cda53-e9f1-4a21-a82c-ee889507b867
Bond, M.
31480405-6e08-4750-9015-0ea2862abe0d
Huxley, N.
703c4699-0f49-418c-8af6-0acb8700e465
Tikhonova, I.
577ccbcc-6643-4190-bb6d-19e13b44bcd1
Hoyle, M.
ebc06a93-bd41-4c23-8c96-1d9e74512c38
Snowsill, T.
33dbf192-8a97-43ed-9317-538d41cf498f
Crathorne, L.
f12cef06-0f01-4a1f-8dde-cbfbfbdaa557
Varley-Campbell, J.
0952839e-b1f4-4e45-b538-6dfc7936f259
Peters, J.
3c661fd3-23a3-4bd9-9379-b98b0a84d28f
Briscoe, S.
741cda53-e9f1-4a21-a82c-ee889507b867
Bond, M.
31480405-6e08-4750-9015-0ea2862abe0d
Huxley, N.
703c4699-0f49-418c-8af6-0acb8700e465

Tikhonova, I., Hoyle, M., Snowsill, T., Crathorne, L., Varley-Campbell, J., Peters, J., Briscoe, S., Bond, M. and Huxley, N. (2016) PCN113 - Cost effectiveness of Cetuximab and Panitumumab for first-line RAS WT metastatic colorecal cancer. Value in Health, 19 (3), A154-A154. (doi:10.1016/j.jval.2016.03.1612).

Record type: Meeting abstract

Abstract

Objectives
Liver resection is a treatment offering long-term survival in patients with metastatic colorectal cancer (mCRC). However, the majority of such patients are not suitable for curative hepatectomy due to widespread nature of their disease. Chemotherapy can significantly downsize primarily unresectable metastases and increase the possibility of resection in mCRC patients. It has been shown that chemotherapy combined with biological agents, cetuximab (CET) and panitumumab (PAN), is clinically beneficial for treating RAS WT tumors (tumors without mutations in KRAS/NRAS exons 2/3/4). This study is aimed: (1) to estimate the cost-effectiveness of combination chemotherapies with CET and PAN for people with previously untreated RAS WT mCRC, not eligible for liver surgery; and (2) to assess CET and PAN against the National Institute for Health and Care Excellence (NICE) end-of-life (EoL) criteria, to inform a Health Technology Assessment for NICE.

Methods
We proposed an economic model estimating costs and benefits of mCRC treatments over patient lifetime horizon. In our base case, we estimated incremental cost-effectiveness ratio (ICER) for CET+FOLFOX versus FOLFOX, PAN+FOLFOX versus FOLFOX, and CET+FOLFIRI versus FOLFIRI. Probabilistic and univariate deterministic sensitivity analyses were performed to estimate uncertainty in model predictions. The cost-utility analysis was based on three randomised controlled trials and undertaken from the NHS and personal social service perspective. Estimated costs and quality-adjusted life years were discounted at 3.5% per annum.

Results
CET and PAN are not cost-effective at willingness-to-pay thresholds of £30,000. Moreover, ICERs remain above £30,000 even under zero prices for CET and PAN. Based on the available evidence, neither CET nor PAN fulfils the NICE EoL criteria to be considered as life-extending EoL treatments.

Conclusions
Although CET and PAN appear to be clinically beneficial for RAS WT patients, they are likely to represent poor value for money when judged by cost-effectiveness criteria used in the UK.

Text
1-s2.0-S1098301516016806-main (1) - Version of Record
Available under License Other.
Download (64kB)

More information

e-pub ahead of print date: 21 May 2016
Published date: May 2016

Identifiers

Local EPrints ID: 437865
URI: http://eprints.soton.ac.uk/id/eprint/437865
ISSN: 1098-3015
PURE UUID: 4df04485-fccd-4eca-a937-b4fadadcbb23
ORCID for I. Tikhonova: ORCID iD orcid.org/0000-0003-2723-0802

Catalogue record

Date deposited: 21 Feb 2020 17:30
Last modified: 12 Dec 2021 08:23

Export record

Altmetrics

Contributors

Author: I. Tikhonova ORCID iD
Author: M. Hoyle
Author: T. Snowsill
Author: L. Crathorne
Author: J. Varley-Campbell
Author: J. Peters
Author: S. Briscoe
Author: M. Bond
Author: N. Huxley

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×